Fibrinogen as a Surrogate for Global Haemostasis in Plasma Exchange
Observational Study of Fibrinogen as a Surrogate for Global Haemostasis in Plasma Exchange Therapy
Sponsor: Hannover Medical School
Terminated
Study was stopped due to recruitment failure
This observational or N/A phase trial investigates Clotting Disorder Due to Plasma Exchange Therapy and Humoral Rejection After Kidney Transplantation and is currently terminated or withdrawn. Hannover Medical School leads this study, which shows 10 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated
-
Sep 2024 — Sep 2025 [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Jan 2021 — Jul 2024 [monthly]
Terminated
-
May 2020 — Jan 2021 [monthly]
Terminated
Status: Suspended → Terminated
▶ Show 5 earlier versions
-
Sep 2019 — May 2020 [monthly]
Suspended
Status: Unknown Status → Suspended
-
Sep 2018 — Sep 2019 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Jun 2018 — Sep 2018 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
Feb 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hannover Medical School
For direct contact, visit the study record on ClinicalTrials.gov .